Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

This study has been terminated.
(An arm closed due to lack of efficacy)
Sponsor:
Collaborator:
Janssen-Cilag International NV
Information provided by:
Lymphoma Study Association
ClinicalTrials.gov Identifier:
NCT00136591
First received: August 26, 2005
Last updated: October 22, 2010
Last verified: October 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2010
  Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)